GlassScriptPhysician profile
Karen Denise Smith
NPI 1114047941
$7,655.46
in general payments reported to CMS, 2019-2025
36 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,044 · 2022: $1,912 · 2023: $1,288 · 2024: $2,150 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,698.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,072.92 | 2021-2025 | Austedo Xr, Uzedy, Ajovy |
| Alexion Pharmaceuticals, INC. | $1,013.62 | 2022-2025 | Ultomiris, Soliris |
| Novo Nordisk INC | $604.84 | 2022-2025 | Wegovy |
| Jazz Pharmaceuticals INC. | $371.64 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $363.08 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $314.84 | 2021-2024 | Lybalvi |
| Bayer Healthcare Pharmaceuticals INC. | $314.25 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $298.35 | 2021-2023 | |
| Amgen INC. | $246.56 | 2022-2023 | Repatha |
| Scynexis, INC. | $148.81 | 2021 | |
| Averitas Pharma INC. | $144.96 | 2025 | Qutenza |
| Silk Road Medical, INC. | $141.60 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Genzyme Corporation | $126.31 | 2025 | |
| Agios Pharmaceuticals, INC. | $124.99 | 2025 | Pyrukynd |
| Gilead Sciences, INC. | $124.99 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $124.74 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $123.75 | 2024 | Hyqvia |
| Biohaven Pharmaceuticals, INC. | $123.08 | 2021 | |
| Pfizer INC. | $122.87 | 2024 | |
| Lilly USA, LLC | $121.86 | 2024 | Omvoh |
| Alnylam Pharmaceuticals INC. | $121.82 | 2023 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $121.35 | 2024 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $119.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $115.48 | 2021 | |
| Idorsia Pharmaceuticals US INC | $115.42 | 2023 | Quviviq |
| Sk Life Science, INC. | $114.48 | 2022 | |
| Edwards Lifesciences Corporation | $108.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Viiv Healthcare Company | $107.10 | 2024 | Dovato |
| Corcept Therapeutics | $100.00 | 2021 | |
| Abbvie INC. | $96.65 | 2022 | |
| Cequr Corporation | $95.85 | 2022 | |
| Eisai INC. | $93.70 | 2025 | |
| Amarin Pharma, INC. | $90.92 | 2024 | |
| Janssen Biotech, INC. | $87.62 | 2022 | |
| Coloplast Corp | $70.76 | 2025 | |
| Boston Scientific Corporation | $68.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.